ALICIA (Acalabrutinib in CLL therapy)

Trial Identifier: D8220R00021
Sponsor: AstraZeneca
NCTID:: NCT04746950
Start Date: February 2021
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Irkutsk, Russia
Russia Kalinigrad, Russia
Russia Khabarovsk, Russia, 680009
Russia Krasnoyarsk, Russia, 660022
Russia Moscow, Russia, 125284
Russia Moscow, Russia, 129110
Russia Nizhniy Novgorod, Russia, 603126
Russia Novosibirsk, Russia, 630091
Russia Saint Petersburg, Russia, 198205
Russia Saratov, Russia, 410028
Russia Tomsk, Russia, 634063
Russia Ufa, Russia, 450054
Russia Yakutsk, Russia, 677008